SCHEMBL4174660

SCHEMBL4174660

CCCCCN(C)CCCCCCCCCC(=O)O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 6/20 0.72
KDM5A P29375 4/20 0.72
PHF8 Q9UPP1 2/20 0.72
GPR84 Q9NQS5 7/20 0.71
PPARG P37231 7/20 0.71
PPARD Q03181 7/20 0.71
PPARA Q07869 7/20 0.71
HDAC11 Q96DB2 5/20 0.71
TSHR P16473 4/20 0.71
PTPN1 P18031 3/20 0.71
ALDH1A1 P00352 2/20 0.71
TLR2 O60603 2/20 0.71
TDP1 Q9NUW8 2/20 0.71
FABP4 P15090 2/20 0.71
SLC22A6 Q4U2R8 1/20 0.71
SLC22A8 Q8TCC7 1/20 0.71
MEN1 O00255 1/20 0.71
ESR1 P03372 1/20 0.71
ALOX15 P16050 1/20 0.71
PDE4A P27815 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dodecanoate SCHEMBL29168497 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG
Dodecanoate SCHEMBL5197487 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG
Myristic Acid SCHEMBL5881282 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG
Palmitic Acid SCHEMBL5198561 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG
Stearic Acid SCHEMBL5371023 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG
Stearic Acid SCHEMBL9782458 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG
Octanoic Acid SCHEMBL9782585 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG
SCHEMBL10988412 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG
SCHEMBL6751342 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG
Palmitic Acid SCHEMBL27443191 1.00 KDM4C (0.72) KDM4CKDM5APHF8GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED 2009-09-10 US claimed
WO-2007005887-A2 ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-01-11 WO claimed
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods AR, NR5A1, ESRRA KDM4C 2219/4885KDM5A 1492/4885PHF8 2956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.